

Nelson Alvis-Guzmán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135521/publications.pdf>

Version: 2024-02-01

240
papers

112,337
citations

10979

71
h-index

2743

192
g-index

274
all docs

274
docs citations

274
times ranked

133687
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.	6.3	9,122
2	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
3	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
4	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
5	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
6	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
7	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
8	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
9	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
10	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
11	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
12	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	1.2	2,705
13	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	4.9	2,625
14	Global, regional, and national burden of stroke and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	4.9	2,308
15	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
16	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
17	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	6.3	2,005
18	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	4.9	2,005

#	ARTICLE	IF	CITATIONS
19	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
20	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
21	Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 691-706.	5.2	1,672
22	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
23	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
24	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
25	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology, The</i> , 2017, 16, 877-897.	4.9	1,521
26	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 165.	3.8	1,492
27	The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. <i>JAMA Oncology</i> , 2017, 3, 1683.	3.4	1,448
28	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
29	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 980-1004.	6.3	1,230
30	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1191-1210.	4.6	1,084
31	Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 585-596.	5.2	1,049
32	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
33	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1211-1228.	4.6	862
34	Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 909-948.	4.6	837
35	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	3.7	823
36	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	6.3	786

#	ARTICLE	IF	CITATIONS
37	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
38	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. <i>JAMA Oncology</i> , 2022, 8, 420.	3.4	719
39	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
40	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
41	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 397, 2337-2360.	6.3	609
42	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
43	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
44	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. <i>BMJ: British Medical Journal</i> , 2019, 364, I94.	2.4	558
45	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
46	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , the, 2016, 3, e361-e387.	2.1	461
47	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
48	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , the, 2019, 6, e831-e859.	2.1	341
49	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
50	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335
51	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	6.3	330
52	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 69-89.	5.2	326
53	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
54	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284

#	ARTICLE	IF	CITATIONS
55	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. <i>Lancet</i> , The, 2019, 393, 2233-2260.	6.3	283
56	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , 2018, 3, 375.	3.0	271
57	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933.	3.7	259
58	The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 261-284.	4.6	246
59	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2021, 398, 870-905.	6.3	229
60	Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 1061-1082.	4.9	221
61	Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 627-647.	3.7	177
62	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
63	Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. <i>Lancet</i> , The, 2022, 400, 185-235.	6.3	161
64	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1329-1349.	4.6	144
65	Diseases, Injuries, and Risk Factors in Child and Adolescent Health, 1990 to 2017. <i>JAMA Pediatrics</i> , 2019, 173, e190337.	3.3	140
66	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 37-59.	4.6	104
67	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 60-79.	4.6	95
68	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet</i> , The, 2021, 398, 503-521.	6.3	93
69	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2021, 398, 1593-1618.	6.3	92
70	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
71	Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , The, 2022, 399, 2129-2154.	6.3	91
72	Is Health Related Quality of Life (HRQoL) a valid indicator for health systems evaluation?. <i>SpringerPlus</i> , 2013, 2, 664.	1.2	90

#	ARTICLE	IF	CITATIONS
73	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Oncology</i> , The, 2022, 23, 27-52.	5.1	90
74	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet</i> , The, 2020, 396, 693-724.	6.3	87
75	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. <i>Lancet</i> , The, 2021, 398, 1317-1343.	6.3	79
76	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. <i>BMC Medicine</i> , 2021, 19, 4.	2.3	78
77	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2020, 395, 1779-1801.	6.3	72
78	Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 177-192.	5.5	66
79	Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 137-149.	1.0	63
80	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. <i>Nature Medicine</i> , 2021, 27, 1761-1782.	15.2	60
81	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , the, 2021, 8, e633-e651.	2.1	56
82	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 222-241.	4.6	53
83	Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 165-176.	1.0	50
84	Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study. <i>International Journal of Public Health</i> , 2018, 63, 151-164.	1.0	48
85	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
86	Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L59-L72.	1.7	46
87	Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries. <i>Vaccine</i> , 2015, 33, 3923-3928.	1.7	45
88	Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 655-667.	5.5	43
89	Impact of carbapenem resistance on clinical and economic outcomes among patients with <i>Acinetobacter baumannii</i> infection in Colombia. <i>Clinical Microbiology and Infection</i> , 2014, 20, 174-180.	2.8	41
90	Global, Regional, and National Levels of Maternal Mortality, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 11-13.	0.2	41

#	ARTICLE	IF	CITATIONS
91	Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. <i>World Allergy Organization Journal</i> , 2018, 11, 26.	1.6	40
92	Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. <i>Vaccine</i> , 2012, 30, 1936-1943.	1.7	38
93	Is Colombia an example of successful containment of the 2020 COVID-19 pandemic? A critical analysis of the epidemiological data, March to July 2020. <i>International Journal of Infectious Diseases</i> , 2020, 99, 522-529.	1.5	35
94	Effectiveness of the monovalent rotavirus vaccine in Colombia: A case-control study. <i>Vaccine</i> , 2014, 32, 3035-3040.	1.7	30
95	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 177-186.	1.0	30
96	Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. <i>Vaccine</i> , 2010, 28, 3856-3864.	1.7	27
97	Burden of Diarrhea in the Eastern Mediterranean Region, 1990–2013: Findings from the Global Burden of Disease Study 2013. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1319-1329.	0.6	27
98	<i>Ascaris lumbricoides</i> infection induces both, reduction and increase of asthma symptoms in a rural community. <i>Acta Tropica</i> , 2018, 187, 1-4.	0.9	25
99	How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case. <i>BMC Health Services Research</i> , 2010, 10, 270.	0.9	23
100	Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. <i>Vaccine</i> , 2011, 29, 7644-7650.	1.7	23
101	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	2.9	23
102	Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011. <i>Value in Health Regional Issues</i> , 2012, 1, 123-128.	0.5	22
103	Treatment costs of diarrheal disease and all-cause pneumonia among children under-5 years of age in Colombia. <i>Vaccine</i> , 2013, 31, C58-C62.	1.7	22
104	Case report: microcephaly associated with Zika virus infection, Colombia. <i>BMC Infectious Diseases</i> , 2017, 17, 423.	1.3	22
105	Risk Factors for Severity of Chikungunya in Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 702-704.	1.1	20
106	Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines. <i>Vaccine</i> , 2013, 31, C80-C87.	1.7	18
107	Economic Costs of Chikungunya Virus in Colombia. <i>Value in Health Regional Issues</i> , 2018, 17, 32-37.	0.5	18
108	Hepatitis B infection control in Colombian Amazon after 15 years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence. <i>Vaccine</i> , 2018, 36, 2721-2726.	1.7	17

#	ARTICLE	IF	CITATIONS
109	Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 79-96.	1.0	17
110	A comprehensive care program achieves high remission rates in rheumatoid arthritis in a middle-income setting. Experience of a Center of Excellence in Colombia. <i>Rheumatology International</i> , 2018, 38, 499-505.	1.5	15
111	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 63-77.	1.0	15
112	Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa550.	0.4	15
113	Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012. <i>Biomedica</i> , 2013, 34, 48.	0.3	13
114	Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990-2015: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 123-136.	1.0	13
115	Burden of diarrhea in the Eastern Mediterranean Region, 1990-2015: Findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 109-121.	1.0	12
116	How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia. <i>Vaccine</i> , 2013, 31, 402-409.	1.7	11
117	Features of Dengue and Chikungunya Infections of Colombian Children under 24 Months of Age Admitted to the Emergency Department. <i>Journal of Tropical Pediatrics</i> , 2018, 64, 31-37.	0.7	11
118	Medical abortion and manual vacuum aspiration for legal abortion protect women's health and reduce costs to the health system: findings from Colombia. <i>Reproductive Health Matters</i> , 2014, 22, 125-135.	1.3	10
119	Economic Cost of Severe Acute Respiratory Infection Associated to Influenza in Colombian Children: A Single Setting Analysis. <i>Value in Health Regional Issues</i> , 2019, 20, 159-163.	0.5	10
120	Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 58.	1.7	10
121	Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e176-e184.	1.1	8
122	Iron status in late pregnancy is inversely associated with birth weight in Colombia. <i>Public Health Nutrition</i> , 2021, 24, 5090-5100.	1.1	8
123	Cost-effectiveness of the subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma: A mathematical model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2229-2233.	2.7	8
124	Ecoepidemiology of Alphaviruses and Flaviviruses. , 2020, , 101-125.		7
125	Dengue, Chikunguña y Zika en Colombia 2015-2016. <i>Revista MVZ Cordoba</i> , 2017, 22, 5994-6003.	0.2	7
126	Estimating costs associated with a community outbreak of meningococcal disease in a Colombian Caribbean city. <i>Journal of Health, Population and Nutrition</i> , 2014, 32, 539-48.	0.7	6

#	ARTICLE	IF	CITATIONS
127	Costos de tratamiento hospitalario de la infección respiratoria aguda grave en niños de Nicaragua. <i>Infectio</i> , 2015, 19, 144-149.	0.4	5
128	Using serological studies to assess COVID-19 infection fatality rate in developing countries: A case study from one Colombian department. <i>International Journal of Infectious Diseases</i> , 2021, 110, 4-5.	1.5	5
129	Economic Impact of Meningococcal Outbreaks in Brazil and Colombia. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv167.	0.4	4
130	Medical care costs of Chikungunya Virus infection in a Pediatric Population in Colombia. <i>Value in Health</i> , 2015, 18, A254-A255.	0.1	4
131	First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 8.	0.7	4
132	Centers of Excellence Implementation for Treating Rheumatoid Arthritis in Colombia: A Cost-Analysis. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 583-591.	0.7	4
133	Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2017, 41, 1.	0.6	4
134	PRS16 AN ECONOMIC EVALUATION OF A PHARMACOLOGICAL INTERVENTION USING VARENICLINE AS THERAPY FOR SMOKING CESSATION. <i>Value in Health</i> , 2009, 12, A123.	0.1	3
135	Cost-Effectiveness Analysis Of Using Hypoglycemic Agents (Linagliptin, Saxagliptin, Sitagliptin,) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> 2013, 16, A163.	0.1	3
136	Diarrheal Deaths After the Introduction of Rotavirus Vaccination in 4 Countries. <i>Pediatrics</i> , 2021, 147, e20193167.	1.0	3
137	Hospitalization costs due to severe acute respiratory infection (SARI) in three Central American countries. <i>Infectio</i> , 2018, 22, 159.	0.4	3
138	Sociodemographic Determinants of child nutrition in Colombia. <i>Salud Uninorte</i> , 2015, 31, 446-457.	0.0	2
139	Economic Impact of Infections and Antibiotics. , 2018, , 11-24.		2
140	Inequalities on mortality due to acute respiratory infection in children: A Colombian analysis. <i>Biomedica</i> , 2018, 38, 586-593.	0.3	2
141	PIN85 GLOBAL COMPLIANCE WITH HEPATITIS B VACCINE BIRTH DOSE AND FACTORS RELATED TO TIMELY SCHEDULE. A LITERATURE REVIEW. <i>Value in Health</i> , 2019, 22, S208.	0.1	2
142	Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 31-39.	1.2	2
143	DENGUE IN AN AREA OF THE COLOMBIAN CARIBBEAN. , 2015, 46, 3-7.		2
144	Education and pneumonia mortality: a trend analysis of its inequalities in Colombian adults. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000695.	1.2	2

#	ARTICLE	IF	CITATIONS
145	A systematic review of observational studies on oxidative/nitrosative stress involvement in dengue pathogenesis. Colombia Medica, 2015, 46, 135-43.	0.7	2
146	PIN26 ECONOMIC EVALUATION OF SUNITINIBVS. INTERFERON-ALFA (IFN-ALFA) IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA. Value in Health, 2008, 11, A100.	0.1	1
147	PCN35 COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE IN COLOMBIA IN 2007. Value in Health, 2009, 12, A42.	0.1	1
148	PIN23 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINE POLYVALENT (PPSV23) IN ADULTS OLDER THAN 60 YEARS OLD IN COLOMBIA. Value in Health, 2010, 13, A190.	0.1	1
149	Inequalities Of The Infant Mortality Rate And Poverty In Colombia. Value in Health, 2013, 16, A78.	0.1	1
150	Economic Costs of Bacterial Meningitis: A Systematic Review. Value in Health, 2015, 18, A807.	0.1	1
151	Hospitalization costs due to severe acute respiratory infection (SARI) in three central American Countries. Value in Health, 2015, 18, A253.	0.1	1
152	Performance of two World Health Organization Dengue classifications in a Pediatric Cohort from Colombia. Value in Health, 2015, 18, A248-A249.	0.1	1
153	Risk Factors of Infant Malnutrition in Cartagena, Colombia: A Case-Control Study. Value in Health, 2016, 19, A174.	0.1	1
154	The Concentration of Health Care Expenditure of a Colombian Public Health Insurance Company. Value in Health, 2016, 19, A32.	0.1	1
155	Socioeconomic Inequalities In Acute Respiratory Infection Mortality Among Children In Colombia. Value in Health, 2016, 19, A121.	0.1	1
156	Social Determinants Of Suicide Attempts In Young People In A Colombian Region. Value in Health, 2016, 19, A186.	0.1	1
157	Opportunity Cost And Health Impact Of Prenatal Care In Pregnant Women With Public Health Insurance In Colombia. Value in Health, 2016, 19, A16-A17.	0.1	1
158	Cost and Effectiveness of the use of Sorafenib in Differentiated Thyroid Cancer. Value in Health, 2017, 20, A876.	0.1	1
159	Prostate Cancer Costs In Colombia: A Top-Down Approach. Value in Health, 2018, 21, S25.	0.1	1
160	Prevalence of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis in Colombia: A Single Setting Study. Value in Health, 2018, 21, S121.	0.1	1
161	Survival of Patients with Diabetes Mellitus By Residential Area in Colombia, 2008-2017. Value in Health, 2018, 21, S77.	0.1	1
162	Efficiency of The use of Long-Acting Reversible Contraception: A Systematic Review of the Literature. Value in Health, 2018, 21, S164.	0.1	1

#	ARTICLE	IF	CITATIONS
163	Costs of acute otitis media in children in a city of the Colombian Caribbean coast. <i>Biomedica</i> , 2019, 39, 75-87.	0.3	1
164	Effectiveness of a prevention program in the incidence of cardiovascular outcomes in a low-income population from Colombia: a real-world propensity score-matched cohort study. <i>BMC Public Health</i> , 2020, 20, 1416.	1.2	1
165	The cost of connecting poor households to natural gas in Colombia and its impact on health, 2007. <i>Revista De Salud Publica</i> , 2012, 14, 28-40.	0.0	1
166	Impacto en el acceso a medicamentos en la población colombiana después de la actualización del plan de beneficios en el 2012. <i>Revista Gerencia Y Politicas De Salud</i> , 2015, 13, .	0.2	1
167	Risk Factors of Chronic Infant Malnutrition in Cartagena, Colombia: A Case-control Study. , 2018, , .		1
168	Prevalencia y factores socioeconómicos asociados al consumo de alcohol en jóvenes de hogares pobres en la subregión Montes de María, en el Caribe colombiano. <i>Revista Facultad Nacional De Salud Publica</i> , 2018, 36, 37-48.	0.1	1
169	Determinantes de estancia prolongada de neonatos en una unidad de cuidados intensivos. <i>Revista Ciencias De La Salud</i> , 2019, 17, 259.	0.1	1
170	PCN8 EVALUACIÓN DE LA CARGA DE ENFERMEDAD POR EL VIRUS DEL PAPILOMA HUMANO EN BOGOTÁ, COLOMBIA. <i>Value in Health</i> , 2009, 12, A494.	0.1	0
171	CS10 ANÁLISIS DE COSTO EFECTIVIDAD Y COSTO UTILIDAD DEL INTERFERÓN BETA-1B (INFB1B) FRENTE A INTERFERÓN BETA-1A (INFB1A) PARA EL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE REMITENTE RECIDIVANTE EN COLOMBIA. <i>Value in Health</i> , 2009, 12, A487.	0.1	0
172	PIN12 EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE NEUMOCOCO EN COLOMBIA. <i>Value in Health</i> , 2009, 12, A517.	0.1	0
173	CS12 IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN COLOMBIA. <i>Value in Health</i> , 2009, 12, A487-A488.	0.1	0
174	PRS45 SMOKING-ATTRIBUTABLE BURDEN OF FOUR TOBACCO-RELATED DISEASES IN COLOMBIA IN 2007. <i>Value in Health</i> , 2009, 12, A129.	0.1	0
175	PIN18 IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE INFLUENZA EN COLOMBIA. <i>Value in Health</i> , 2009, 12, A518.	0.1	0
176	PIN8 EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE COLOMBIA. <i>Value in Health</i> , 2009, 12, A516.	0.1	0
177	CS17 COSTOS DE LA ESCLEROSIS MÚLTIPLE EN COLOMBIA. <i>Value in Health</i> , 2009, 12, A491.	0.1	0
178	PIN28 COST-EFFECTIVENESS ANALYSIS OF CHANGING FROM LIVE ORAL POLIOVIRUS VACCINE TO INACTIVATED POLIOVIRUS VACCINE IN COLOMBIA. <i>Value in Health</i> , 2010, 13, A191.	0.1	0
179	PIH4 Analisis De Costo-Efectividad Del Uso De Levonorgestrel-Uis Frente A Otros Tratamientos En Menorragia Idiopatica. <i>Value in Health</i> , 2011, 14, A558.	0.1	0
180	PDB9 Analisis De Costo-Efectividad Del Uso De Detemir En Diabetes Tipo 2 Frente Al Riesgo De Presentar Eventos Cardiovasculares Y Muerte. <i>Value in Health</i> , 2011, 14, A547.	0.1	0

#	ARTICLE	IF	CITATIONS
181	QA2 Analisis De Costo-Utilidad De Rituximab Posterior Al Fallo Por Anti-Tnf En Artritis Reumatoide Para Colombia. Value in Health, 2011, 14, A536.	0.1	0
182	PIN22 COST-EFFECTIVENESS OF A CATCH-UP DOSE OF HEPATITIS B VACCINE IN COLOMBIAN ADOLESCENTS. Value in Health, 2011, 14, A117.	0.1	0
183	PIN27 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF ACELLULAR PERTUSSIS IN COLOMBIAN ADOLESCENTS. Value in Health, 2011, 14, A118.	0.1	0
184	PRS39 EFFECT OF BIOMASS SMOKE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RURAL LOCALITIES OF COLOMBIA. Value in Health, 2011, 14, A144.	0.1	0
185	PIH1 Impacto Presupuestal Del Uso De Levonorgestrel-Uis Frente A Otros Tratamientos En Menorragia Idiopatica En Colombia. Value in Health, 2011, 14, A557.	0.1	0
186	HS2 Analisis De Costos Del Programa Ampliado De Inmunizaciones En Colombia 2009. Value in Health, 2011, 14, A539.	0.1	0
187	PMS65 Quality of Life in Patients with Rheumatoid Arthritis in Biological Therapy in Colombia. Value in Health, 2012, 15, A45.	0.1	0
188	PRM18 Review of Administration's Cost Assumption of Rotavirus and Pneumococcal Vaccines Cost-Effectiveness Analyses. Value in Health, 2012, 15, A162.	0.1	0
189	PCN65 Cost-Effectiveness Analysis of Introducing HPV Vaccines in Colombian Women. Value in Health, 2012, 15, A420.	0.1	0
190	PCN60 Cost Effectiveness of Nilotinib, Dasatinib and Imatinib as First Line Treatment of Chronic Myeloid Leukemia in Colombia 2011. Value in Health, 2012, 15, A218.	0.1	0
191	Costos Económicos Asociados A Secuelas De Meningitis En Colombia. Value in Health, 2013, 16, A712-A713.	0.1	0
192	Análisis Del Impacto En La Demanda De Tecnologías Incluidas En El Plan De Beneficios Colombiano (POS) Posterior A Su Actualización En 2012. Value in Health, 2013, 16, A670.	0.1	0
193	Potential Epidemiological And Economic Impact Of Different Rotavirus Vaccines In Low And Middle Income Countries. Value in Health, 2013, 16, A91.	0.1	0
194	Cost-Effectiveness Analysis Of Introduction Of Meningococcal Conjugate Vaccine In Colombia, 2011. Value in Health, 2013, 16, A89-A90.	0.1	0
195	Epidemiological and Economic Impact of Chronic Kidney Disease in Patients with Hypertension and Diabetes in Colombia. Value in Health, 2013, 16, A671.	0.1	0
196	Effectiveness Of The Monovalent Rotavirus Vaccine In Colombia Through Different Analyses Within An Ecological Study. Value in Health, 2013, 16, A80.	0.1	0
197	Effectiveness Of The Rotavirus Monovalent Vaccine In Colombia: Preliminary Results Of A Case-Control Study. Value in Health, 2013, 16, A81.	0.1	0
198	Cost Of Outbreak Of Meningococcal Disease In A Colombian Caribbean City, 2012. Value in Health, 2013, 16, A87.	0.1	0

#	ARTICLE	IF	CITATIONS
199	Infant mortality in a university pediatric hospital in Colombia, 2000 – 2010. Salud Uninorte, 2015, 31, 10-17.	0.0	0
200	Costos económicos de la otitis media aguda. Una revisión de la literatura. Value in Health, 2015, 18, A869-A870.	0.1	0
201	Mortality In A University Pediatric Hospital In Colombia 2000 – 2014. Value in Health, 2015, 18, A833.	0.1	0
202	Burden of disease of Hepatitis C in Colombia. Value in Health, 2015, 18, A250-A251.	0.1	0
203	The Use of Heliox in Hospitalized Children From Cartagena Colombia. Value in Health, 2015, 18, A170.	0.1	0
204	Prognostic capabilities and agreement of three different scores in diagnosing appendicitis in children from a developing setting. Annals of Pediatric Surgery, 2016, 12, 5-9.	0.1	0
205	Avoidable Hospitalizations Through Effective Primary Care At A Pediatric Hospital In The Colombian Caribbean. Value in Health, 2016, 19, A627.	0.1	0
206	Out-Of-Pocket Health Expenditures In Patients With Uncontrolled Asthma From Colombia. Value in Health, 2016, 19, A16.	0.1	0
207	Socioeconomic Determinants of Nutritional Status in Outpatients Under Five in a Pediatric Hospital of Colombia. Value in Health, 2016, 19, A180.	0.1	0
208	Costs of Non-Adherence in Hypertensive Patients Affiliates to Health Insurance in Cartagena. Value in Health, 2016, 19, A33.	0.1	0
209	Risk Factors and Socioeconomic Determinants of Child Abuse: A Case-Control Study in Patients in a Pediatric Hospital in Colombia. Value in Health, 2016, 19, A174.	0.1	0
210	SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF ALTERNATE IMMUNIZATION STRATEGIES TO CONTROL MENINGOCOCCAL MENINGITIS. Value in Health, 2016, 19, A218.	0.1	0
211	Aspects Of Family Life In Young People In A Region Of Colombia In 2014. Value in Health, 2016, 19, A12.	0.1	0
212	Prevalence and Risk Factors of Alcohol Consumption in Young Poor People with Public Health Insurance from a Region of Colombia. Value in Health, 2016, 19, A33.	0.1	0
213	Social Determinants of Young Pregnancy in Colombia. Value in Health, 2016, 19, A174-A175.	0.1	0
214	Prevalence Of Use Of Contraceptive Methods In Young Poor People From A Region Of Colombia. Value in Health, 2016, 19, A100.	0.1	0
215	Conventional and Biological Therapy in Patients with Rheumatoid Arthritis. A Cost Analysis in Colombia. Value in Health, 2017, 20, A938.	0.1	0
216	Low Birth Weight in Newborns and Associated Maternal and Neonatal Factors in a Colombian Gineco-Obstetrical Hospital. Value in Health, 2018, 21, S105.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Malnutrition and Vaccination in Children: Case of Post-Conflict Zone in Colombian Caribbean. Value in Health, 2018, 21, S147.	0.1	0
218	Costs and Trends in the Usage of Biological Therapy for Rheumatoid Arthritis - A Retrospective Study. Value in Health, 2018, 21, S195.	0.1	0
219	Costs Related to Infusion Therapy Room and Staff for Rheumatoid Arthritis in a Specialized Center. Value in Health, 2018, 21, S124.	0.1	0
220	Ultrasound: A Fast Low-Cost Tool for the Diagnosis of Rheumatoid Arthritis in a Specialized Center. Value in Health, 2018, 21, S172.	0.1	0
221	Infant Mortality from Acute Respiratory Infections and Armed Conflict: An Exploratory Analysis. Value in Health, 2018, 21, S134.	0.1	0
222	Armed Conflict and Infant Mortality Due to Diarrhea in Colombian Children. Value in Health, 2018, 21, S133.	0.1	0
223	Effectiveness and Costs of Conventional Dmard Therapy in Patients with Rheumatoid Arthritis. Value in Health, 2018, 21, S196.	0.1	0
224	Efficacy and Safety Analysis of Radium-223 in Patients with Prostate Cancer Castration-Resistant and Bone Metastasis. Value in Health, 2018, 21, S16-S17.	0.1	0
225	PRS39 EDUCATIONAL INEQUALITY TRENDS IN MORTALITY DUE TO PNEUMONIA IN COLOMBIA, 1998-2015. Value in Health, 2019, 22, S356.	0.1	0
226	PCV7 EFFECTIVENESS OF A CARDIOVASCULAR RISK MANAGEMENT PROGRAM IN THE REDUCTION OF PREMATURE MORTALITY ASSOCIATED TO CARDIOVASCULAR EVENTS IN THE CARIBBEAN REGION OF COLOMBIA. Value in Health, 2019, 22, S119.	0.1	0
227	PIN28 COST-EFFECTIVENESS OF QUADRIVALENT (6,11,16,18) HPV VACCINATION IN 9 TO 10 YEARS OLD FEMALES AT DIFFERENT COVERAGE RATES IN COLOMBIA. Value in Health, 2019, 22, S198.	0.1	0
228	PMS19 POTENTIAL COST-SAVINGS DUE TO THE APPLICATION OF A CENTER OF EXCELLENCE CARE MODEL IN RHEUMATOID ARTHRITIS IN COLOMBIA. Value in Health, 2019, 22, S241.	0.1	0
229	PMS25 CHARACTERISTICS AND MONETARY COMPENSATION OF CAREGIVERS FOR PATIENTS WITH RHEUMATIC CONDITIONS. Value in Health, 2019, 22, S242-S243.	0.1	0
230	PMS21 HOW EXPENSIVE IS TREATING PATIENTS IN A CENTER OF EXCELLENCE FOR RHEUMATOID ARTHRITIS IN COLOMBIA?. Value in Health, 2019, 22, S242.	0.1	0
231	PDB78 PREVALENCE OF FAMILIAL HYPERLIPIDEMIA IN THE ADULT POPULATION OF THE COLOMBIAN CARIBBEAN. Value in Health, 2019, 22, S153-S154.	0.1	0
232	PCV5 PREVALENCE OF FOUR STATIN BENEFIT GROUPS IN A POPULATION OF THE CARIBBEAN REGION OF COLOMBIA. Value in Health, 2019, 22, S118-S119.	0.1	0
233	AB1235€...COST-SAVING FOR HEALTH SERVICES DETECTING THE MISDIAGNOSIS OF RHEUMATOID ARTHRITIS USING IMAGING IN THE PROCESS OF DIAGNOSIS: EVIDENCE FROM REAL-WORLD. , 2019, , .		0
234	Antimicrobial resistance trends in methicillin-resistant and methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis isolates obtained from patients admitted to intensive care units. 2010-2015. Revista Facultad De Medicina, 2019, 67, 221-228.	0.0	0

#	ARTICLE	IF	CITATIONS
235	PIN58 PREVALENCE OF PARASITE INTESTINAL INFECTIONS IN A RURAL COMMUNITY OF THE CARIBBEAN NORTH OF COLOMBIA. Value in Health, 2019, 22, S204.	0.1	0
236	PMS1 PREVALENCE OF JUVENILE IDIOPHATIC ARTHRITIS IN COLOMBIA. Value in Health, 2019, 22, S239.	0.1	0
237	PIN102 ARE LIVER-RELATED MORTALITY RATES DECREASING AFTER HEPATITIS B VACCINATION? CHALLENGES AND OPPORTUNITIES IN ASSESSING THE IMPACT OF HBV VACCINATION ON MORTALITY BY LIVER DISEASES IN DEVELOPING COUNTRIES. AN ECOLOGICAL ANALYSIS OF COLOMBIAN DATA. Value in Health, 2019, 22, S211.	0.1	0
238	Factores de severidad de Neumonía Adquirida en la Comunidad en un hospital infantil del Caribe colombiano. Salud Uninorte, 2019, 34, 302-314.	0.0	0
239	Epistemología del cáncer de mama: comprendiendo su origen para anticipar su desenlace. Revista Colombiana De Cancerología, 2021, 25, .	0.0	0
240	Medición de la calidad de vida de pacientes con artritis reumatoide atendidos en el Hospital Universitario del Caribe, Bolívar, Colombia. Revista Ciencias Biomédicas (cartagena), 2021, 10, 246-255.	0.0	0